Clinical trial · Interventional
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
NCT00850278CI-TRIAL-00107174FLTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to assess the efficacy of the radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a tracor of cell proliferation, using Positron Emission Tomography (PET) imaging for the tumor diagnosis and prognosis in a group of 50 patients with different type of brain tumors.\[F-18\]FLT PET imaging will be compared to the current used imaging techniques of MRI, spectroscopy imaging, PET imaging using \[11C\]MET tracer, immunohistochemical analysis and clinical parameters.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumors | Brain Neoplasm | ALIAS | 0.90 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLT-PET imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FLT-PET imaging
- description
- Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
- interventionNames
- Other: FLT-PET imaging
Primary outcomes (1)
- measure
- To evaluated the aggressive potential of brain tumors related to cell proliferation index measured by [18F]FLT
- timeFrame
- Day 10
Secondary outcomes (3)
- measure
- To compare the efficiency of [18F]FLT with [11C]MET
- timeFrame
- Day 15
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adults aged between 18 and 70 years * must have operable grade II, III or IV glioma, recurrent high grade glioma or brain metastases * KPS \>= 70% * must have the understanding and ability to sign an informed consent document * must have adequate liver and kidney function * be male or non-pregnant, non-lactating females * patients who are fertile must agree to use an effective method of contraception during participation in the study * the following laboratory results : absolute neutrophil count \>= 1500 cells/µl, platelet count \>= 100000 cells/µl, SGOT \<= 2.5 x ULN, serum creatinine \<= 1.5 x ULN. Exclusion Criteria: * contraindication to surgery * concomitant radio-, chemo-, or immunotherapy * history of significant dementia * known diagnosis of Human Immunodeficiency Virus (HIV) infection * patient with hepatitis B or C
References
Publications (1)
- RESULTCollet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, Abbas A, Ibazizene M, Bernaudin M, Barre L, Derlon JM, Guillamo JS. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin. 2015 May 29;8:448-54. doi: 10.1016/j.nicl.2015.05.012. eCollection 2015. PMID 26106569